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A case of chickenpox in a 94-year-old female is described. Serological tests for Varicella zoster virus (VZV) performed on early
and late serum samples conﬁrmed primary VZV infection. The patient recovered but seventeen days after presentation she
developed a stroke from which she subsequently died. Chickenpox in older people is relatively rare—this case may be the oldest
case of laboratory-proven chickenpox described—but it is a life-threatening illness. The varicella vaccine is licensed for use in
immunocompetent persons of 12 months of age or older but in the UK is only oﬀered to susceptible healthcare workers and close
contacts of immunocompromised patients. In the US, the vaccine is recommended for all susceptible adolescents and adults. The
same recommendation should be made in the UK.
1.Introduction
Chickenpox is considered a universal childhood infection in
temperate parts of the world with >90% seropositivity by
adolescence. If missed during childhood the next most likely
time of exposure to VZV is probably when young adults have
children of their own. A case of chickenpox is described in a
94-year-old femalewhohadnot hadchildren.Chickenpox in
older people is uncommon but life-threatening and could be
prevented by wider use of varicella vaccine than is currently
recommended in the UK. A case for this is made in light
of relatively recent recommendations on the wider use of
varicella vaccine in the US.
2.CaseReport
A woman aged 94 years (and 50 weeks) presented to her
general practitioner with a widespread rash of approximately
48-hour duration. She volunteered that she had never
had chickenpox and that her husband had experienced
ophthalmic zoster three weeks previously. On examination
she did not appear unwell and was apyrexial. There was
a vesicular rash on her face, limbs, and trunk consistent
with chickenpox and no sign of localisation to a single
dermatome. Famciclovir 250mg, 8-hourly was started. On
review, the following day the rash was very typical of
chickenpox with some crusting of older lesions. She felt weak
but remained apyrexial and had no chest symptoms or signs.
Serum collected on this second day of clinical review was
positive for Varicella zoster virus (VZV) IgM antibody by
enzyme immunoassay (EIA) (Trinity biotech) and negative
for VZV IgG (EIA) consistent with early chickenpox infec-
tion. A second serum collected two days later showed the
same VZV serology results, except that the IgM was even
more reactive. A third follow-up serum collected a further
ﬁfteendayslaterrevealedVZVIgGseroconversiontopositive
(strongly reactive) with the IgM remaining positive. The
results conﬁrmed primary VZV infection. A viral swab of the
skin lesions was not collected.
Seven days after initial presentation the patient was
recovering well and all skin lesions had crusted with earlier
ones clearly showing signs of healing. A further ten days
later, after making a full recovery, the patient suddenly
developed a dense hemiplegia from which she died a month2 Case Reports in Medicine
later. Computerised tomography conﬁrmed an acute right
hemisphere brain infarct associated with the middle cerebral
artery. A postmortem was not performed.
3. Discussion
The absence of VZV-speciﬁc IgG antibody early in a
chickenpox-like illness can be taken as evidence of primary
VZV infection once subsequent seroconversion to IgG
positive is demonstrated. It is well known that cell-mediated
immunity to VZV wanes with old age, and that this is
the mechanism of reactivated disease, but antibody levels
can be expected to persist, even into the ninth and tenth
decades of life in otherwise healthy older people [1]. This
fact, together with the conﬁdent history volunteered by
the patient described that she had never had chickenpox,
satisﬁed us that this was a clear case of primary VZV
infection.
The patient described was unlucky to be exposed to
varicella virus for the ﬁrst time at such a late age—
the exposure almost certainly coming from her husband’s
ophthalmic zoster. A review of the literature reveals patients
withchickenpoxat86[2],87[3],and88yearsofage[4]with
only the 87 year-old male surviving the illness. The patient
described in this case report may be the oldest laboratory-
proven case of chickenpox recorded.
A weakened cell-mediated immunity that we might
expect in an elderly person would predispose to a more
severe primary illness. Delayed or weakened virus-speciﬁc
T-cell recognition has been shown to correlate with a more
serious outcome in chickenpox [5]. Complications, such as
pneumonitis, encephalitis, and secondary bacterial infection
of skin lesions can also have more severe consequences in
olderpeople. Tobeeﬀective,oralantiviralsneedtobestarted
within 24 hours of onset of the chickenpox rash so it is
unlikely that the famciclovir course (unlicensed in the UK if
usedforchickenpox)inthepatientdescribedwasresponsible
for her uncomplicated recovery. It is interesting to speculate
that the patient’s hemiplegia was a brieﬂy delayed compli-
cation of the chickenpox. Delayed contralateral hemiplegia
is a well-described complication of ophthalmic zoster but
delayed hemiplegia is also recognised as a rare complication
of chickenpox in children [6]. Cerebrospinal ﬂuid was
not collected from the patient nor was postmortem tissue
available for histological studies which might have provided
evidencetosupportacausalassociationwiththechickenpox.
The patient also suﬀered atrial ﬁbrillation and was not on
warfarin so an embolic event associated with this condition
might have been the sole cause of her stroke.
A live-attenuated varicella vaccine has been licensed for
use in immunocompetent persons of 12 months of age or
older for some years in the UK, but it is currently only
oﬀered to susceptible healthcare workers and household
contacts of immunocompromised patients [7]. In the US
the vaccine has been included in the routine childhood
vaccination schedule since 1995 and it has been successful
in reducing chickenpox morbidity and mortality, but it has
only recently been formally recommended for all susceptible
adolescents and adults [8]. Although no particular age group
of adults is speciﬁed in the American recommendations it
is generally assumed that the vaccine is not likely to be
required by today’s older adults, at least not to prevent
chickenpox. Instead, studies on the use of varicella vaccine in
the elderly have all been aimed at the prevention of Herpes
zoster and this has required higher potency of Varicella
zoster virus (OKA strain) than the 1350 plaque-forming
units (PFU) contained in each 0.5mL of “Varivax” vaccine
(Merck). The recently licensed zoster vaccine, “Zostavax”
(Merck) in the US has a potency of at least 14 times that of
Varivax [9]. However, this does not mean that high potency
is necessarily required to prevent chickenpox in the elderly.
Trannoy et al. [10] achieved increased humoral and cell-
mediated immunity in elderly subjects with a single dose of
vaccine containing a potency of virus as low as 3200 PFU
and did not try any lower potency. For adults, two doses
of varicella vaccine are recommended (4–8 weeks apart);
whether or not this will provide suﬃcient potency for older
persons may never be tested in a clinical trial but we believe
thatsusceptibleelderlyindividuals—andwehaveshownthey
occur—could beneﬁt. It would be useful to have case reports
of individual elderly patients with their immunogenicity
tested post vaccine; this would probably require, in addition
totestsofcell-mediatedimmunity, moresensitiveserological
tests (such as the Time-Resolved Fluorescence Immunoassay
[11]) than is routinely available in most medical virology
laboratories as most commercial assays lack sensitivity to
always detect vaccine-induced immunity to VZV [8].
In the UK, and other countries, the use of varicella
vaccine in healthy children remains controversial; longer
scrutiny of the cost beneﬁts appears to be required. However,
given the high risks associated with primary VZV infection
in adulthood, it is hard to conceive why varicella vaccine
cannot be oﬀered to all susceptible adolescents and adults. If
elderly persons are considered, in general, to be an unreliable
group to question about a past history of chickenpox,
either routinely or after exposure, at least the vaccination of
younger adults may prevent even more serious disease when
they are much older.
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